Oct. 20, 2021, 8:00 a.m. EDT

BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    BioVaxys Technology Corp. (BIOV)

or Cancel Already have a watchlist? Log In

VANCOUVER, BC, Oct. 20, 2021 (Canada NewsWire via COMTEX) -- BioVaxys Technology Corp. /zigman2/quotes/209221990/delayed CA:BIOV +4.76% , (fra:5LB), (otcqb:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United States Patent & Trademark Office ("USPTO") a provisional patent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all sarbecoviruses, the family of Coronaviruses that includes SARS-CoV-2, which causes Covid-19.

A recent study(1) published in the New England Journal of Medicine ("NEJM") evaluated human volunteers who had natural immunity to SARS-Cov-1 (a coronavirus similar to SARS-CoV-2 but with higher mortality), which broke out in 2003 and is often referred to as the first global pandemic of the 21(st) century(2), and who were immunized against SARS-CoV-2 with a widely used mRNA vaccine. The result was surprising: the recipients had neutralizing antibody not only to SARS-CoV-1 and SARS-CoV-2, but also to eight other sarbecoviruses, including emerging zoonotic sarbecoviruses that may have future pandemic potential. This cross-reactivity was due to similarities in the S-spike protein. Sarbecoviruses, such as SARS-CoV-1 and SARS-CoV-2, all bind to the ACE2 receptor, which makes them highly transmissible.

Biovaxys intends to leverage its haptenized viral protein vaccine platform to induce immunity against all or most sarbecoviruses by immunizing people who have convalesced from a documented Covid-19 infection, or received a full course of any Covid-19 vaccine recognized by the World Health Organization, with a novel vaccine composed of the dinitrophenyl ("DNP")-modified S-spike protein of SARS-CoV-1.

Dr. David Berd, Chief Medical Officer of BioVaxys, commented: "Scientists dream of a pan-Coronavirus vaccine that would protect the population against any SARS-like respiratory virus that might mutate and emerge from a wild animal in the future. Our approach could constitute a pan-sarbecovirus vaccine that would protect humans against a very dangerous subgroup of Coronavirus that could emerge from the wild and cause as much devastation as Covid-19."

James Passin, Biovaxys Chief Executive Officer, stated, "There have been over 217 million recoveries following confirmed cases of Covid-19 ( www.statista.com ) and 6.6B doses have been given of Covid-19 vaccine (Bloomberg Oct 15 2021); this total target population of almost 4 billion people represents a massive commercial opportunity for proposed our pan-sarbecovirus booster vaccine, which has the potential to confer cross-reactive neutralizing antibodies, not only against all Covid-19 variants, but future emerging dangerous zoonotic sarbecoviruses."

For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.

1) N Engl J Med 2021; 385:1401-1406 DOI: 10.1056/NEJMoa2108453

2) Journal of Emerg Infect Dis. 2004 Nov; 10(11), SARS, the First Pandemic of the 21 Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

(†)Boston Public Health Commission, Boston, Massachusetts, USA

st Century(,)James W. LeDuc(,)Center for Disease Control & Prevention, Atlanta GA and M. Anita Barry, Boston Public Health Commission, Boston, MA Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

(†)Boston Public Health Commission, Boston, Massachusetts, USA Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

(†)Boston Public Health Commission, Boston, Massachusetts, USA

About BioVaxys Technology Corp.

Based in Vancouver, BioVaxys Technology Corp. ( www.biovaxys.com ) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has multiple issued US patents and pending patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (fra:5LB) and in the US (otcqb:BVAXF).


Signed "James Passin"

James Passin, CEO +1 646 452 7054

Cautionary Statements Regarding Forward Looking Information

CA : Canadian Securities Exchange
$ 0.11
+0.0050 +4.76%
Volume: 11,000
June 30, 2022 9:45a
P/E Ratio
Dividend Yield
Market Cap
$9.17 million
Rev. per Employee
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.